1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Austria >
  5. Biosynth Acquires EUCODIS Bioscience

M&A Deal Summary

Biosynth Acquires EUCODIS Bioscience

On January 1, 2022, Biosynth acquired life science company EUCODIS Bioscience from PONTIS Capital

Acquisition Highlights
  • This is Biosynth’s 1st transaction in the Life Science sector.
  • This is Biosynth’s 1st transaction in Austria.

M&A Deal Summary
Date 2022-01-01
Target EUCODIS Bioscience
Sector Life Science
Buyer(s) Biosynth
Sellers(s) PONTIS Capital
Deal Type Add-on Acquisition

Target

EUCODIS Bioscience

Vienna, Austria
EUCODIS Biosciencedevelops, customizes, manufactures, and markets industrial enzymes. EUCODIS Bioscience’ products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties. The Company offers a broad portfolio of novel enzymes, including lipases, phospholipases, and beta-lactamases. EUCODIS Bioscience is based in Vienna, Austria.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Biosynth

St. Gallen, Switzerland
Category Company
Founded 1965
Sector Chemicals
DESCRIPTION

Biosynth is a fully hybrid research products, life sciences reagents and custom synthesis and manufacturing services company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products. Biosynth was formed in 1965 and is based in St. Gallen, Switzerland.

DEAL STATS #
Overall 1 of 8
Sector: Life Science M&A 1 of 7
Type: Add-on Acquisition M&A Deals 1 of 8
Country: Austria M&A 1 of 1
Year: 2022 M&A 1 of 4
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-17 vivitide

Gardner, Massachusetts, United States

vivitide is a provider of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. vivitide was founded in 1998 and is based in Gardner, Massachusetts.

Buy -

Seller(S) 1

SELLER

PONTIS Capital

Vienna, Austria

Investor

Category Growth Capital Firm
Founded 2005
PE ASSETS 90M EUR
Size Small
Type Sector Focused
DESCRIPTION

PONTIS Capital is a private investment group focused on high-growth tech businesses in Central Europe. PONTIS looks to invest €1 to €5 million in businesses generating €2 to €40 million in sales. PONTIS seeks companies with experienced management, 'proof of market', and 'scalable business models that can be applied internationally'. Sectors of interest include information/communication technologies, clean technology, and life sciences. PONTIS was formed in 2005 and is based in Vienna.

DEAL STATS #
Overall 7 of 8
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 5 of 6
Country: Austria M&A 6 of 6
Year: 2022 M&A 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-09-12 Lixto Software

Vienna, Austria

Lixto provides innovative search technology delivering structured results from Web queries. Both businesses and consumers use Lixto technology to derive more relevant and better structured results from the Web than normal search engines provide. Lixto delivers solutions in the area of metasearch, online market intelligence and Web process integration.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-09 evidanza

Straubing, Germany

evidanzaas is a software company that develops its own business intelligence solutions based on Microsoft technologies. evidanza was founded in 2004 and is based in Straubing, Germany.

Sell -
Mergr

Solution for

Product

Company

Legal